NCT02763566: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with inflammatory breast cancer (IBC); Patients with clinical evidence or a history of central nervous system (CNS) metastasis
https://ClinicalTrials.gov/show/NCT02763566

Comments are closed.

Up ↑